Chronic kidney disease stage 2-4
Conditions
Interventions
Up-titration statin therapy
Ezetimibe Added-on statin therapy
Sponsors
Hiromichi Suzuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CKD stage 2-4 2) LDL-C levels with statin therapy is 120mg/dL or more 3) Aged from 35 years to 75 years
Exclusion criteria
Exclusion criteria: 1 total glyceride less than 400mg dl 2 liver enzyem less than 2 times the upper limit of normal] 3 patients withhomozygous familial hypercholesterolemia 4 patients with homozygous familial hypercholesterolemia 5 within 3 months of study entry of unstable angian, myocardial infarction, surgical coronary intervention or stroke 6 patients who are pregnant or nursing mohters, patients who may be pregnant, or patients who want to become pregnant during participation in the study 7 patients with a hisotry of hypersensitiivity to nay ingredient of ezetimibe tablets 8 other patients deemed not appropriate for study entry by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety Surveillance of ezetimibe added to statin therapy vs up-titration statin therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy Surveillance of ezetimibe added to statin therapy vs up-titration statin therapy | — |
Countries
Japan
Contacts
Public ContactHiromichi Suzuki
Saitama Medical University Department of Nephrology
Outcome results
None listed